TSC22D1

Across TCGA pan-cancer cohorts, TSC22D1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TSC22D1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TSC22D1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TSC22D1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where TSC22D1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TSC22D1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.434	<.001	9	view →
LUAD	Female	II,III,IV	−0.344	<.001	9	view →
LSCC	Male	III,IV	−0.534	<.001	8	view →
HNSC	Male	All	−0.366	<.001	8	view →
PDAC	All	All	+0.238	.007	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TSC22D1–CCRCC

Open the CCRCC breakdown →